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Abstract 
Case report and literature review on translocation 
t(5;6)(q33-34;q23) in an acute myelomonocytic 
leukemia patient. 
Clinics 
Age and sex 
68 years old female patient. 
Previous history 
No preleukemia, no previous malignancy, no inborn 
condition of note, no main items.  
Organomegaly 
No hepatomegaly, no splenomegaly, no enlarged 
lymph nodes, no central nervous system 
involvement.  
Blood 
WBC: 104 X 109/l 
HB: 7.8g/dl 
Platelets: 57 X 109/l 
Blasts: 84% 
Bone marrow: Hypercellular marrow with 87% 
blasts which were PAS diffuse granular positive 
and SBB (Sudan Black B) positive. 
Cyto-Pathology 
Classification 
Cytology 
Acute myelomonocytic leukemia 
 
 
Immunophenotype 
Positive for CD13, CD15, CD117, CD33, MPO, 
CD45, HLDR and dim CD34 (27%) 
Diagnosis 
Acute myelomonocytic leukemia 
Survival 
Date of diagnosis: 03-2013 
Treatment: Chemotherapy (Daunorubicin & 
Cytarabine combination therapy; consolidation with 
high dose Ara-C) 
Complete remission: no  
Treatment related death: no  
Relapse: yes 
Phenotype at relapse: Acute myelomonocytic 
leukemia 
Status: Lost 
Last follow up: 11-2013 
Survival: 8 months 
Karyotype 
Sample: Bone marrow, blood 
Culture time: 24h 
Banding: G-banding 
Results 
46,XX,t(5;6)(q33-34;q23)[25] 
Karyotype at Relapse 
46,XX,t(5;6)(q33-34;q23)[1]/46,XX,t(5;6)(q33-
34;q23),t(7;10)(p22;q23)[19] 
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Figure 1. A. Karyotype from the time of diagnosis showing the chromosomal translocation t(5;6)(q33-34;q23). B. Fluorescence in 
situ hybridization studies (FISH) with XL 6q21/6q23 (Metasystem, Germany) probe showing red and green signals on both, 
normal and der(6) chromosomes. C. Applying the XL PDGFR probe (Metasystem, Germany) showed normal signal pattern on 
both normal and der(5) chromosomes, indicating that PDGFR located on 5q32-33 is not involved in the translocation. D. 
Hybridization with whole chromosome 6 probe (Metasystem, Germany) showing translocation of chromosome 6 sequences to 
der(5) chromosome. 
 
 
Other molecular cytogenetics technics 
Fluorescence in situ hybridization (FISH) with LSI 
AML1-ETO, LSI MLL, LSI CBFB/inv(16), LSI 
EGRI/5q31 (Abbott Molecular, Downers Grove, 
IL) and XL 6q21/6q23, XL PDGFR, whole 
chromosome 6 probe Metasystem, Germany). 
Other molecular cytogenetics results 
Normal signal patterns for LSI AML1-ETO, LSI 
MLL, LSI CBFB/inv(16), LSI EGRI/5q31, XL 
6q21/6q23 and XL PDGFR probes. 
Comments 
Chromosomal translocations involving 5q33 and 
6q23 have been reported in only one patient with T- 
 
 
 
 
ALL and an associated myeloproliferative 
neoplasm and C6ORF204/PDGFRB fusion 
(Chmielecki et al 2012).  
While in this case, the chromosomal translocation 
appeared to be morphologically identical to our 
t(5;6)(q33-34;q23), in our patient PDGFRB (5q32-
33) is not rearranged and MYB (6q23)is not 
translocated to chromosome 5 as in a previously 
described case.  
Due to the availability of tyrosine kinase inhibitors 
for PDGFRB rearranged disorders, our findings 
emphasize the importance of FISH in precise 
characterizing of chromosome rearrangements with 
5q33-34 breakpoints, especially in suboptimal 
preparations. 
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Figure 2. A. Karyotype from blood cell from the time of relapse showing the t(5;6)(q33-34;q23) and a new anomaly 
t(7;10)(p22;q23). B. Partial karyotypes from blood and bone marrow showing the t(5;6)(q33-34;q23). 
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